External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Reported revenue grew by 35.3% YoY and was majorly contributed by Biosimilars (+53.5% YoY) and generics (+18.1% YoY).</li><li>Adj. PAT of Rs 251 Cr increased by 14.2% YoY after adjusting one-time costs of Rs 271 Cr which arose due to the Viatris deal.</li><li>Existing and new products (bAdalimumab, bBevacizumab, bAspart) in Europe and Emerging Markets added growth in the last quarter.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Reported revenue grew by 35.3% YoY and was majorly contributed by Biosimilars (+53.5% YoY) and generics (+18.1% YoY).Adj. PAT of Rs 251 Cr increased by 14.2% YoY after adjusting one-time costs of Rs 271 Cr which arose due to the Viatris deal.Existing and new products (bAdalimumab, bBevacizumab, bAspart) in Europe and Emerging Markets added growth in the last quarter.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon Ltd - Aggressive Capital Allocation Led to Suppressed Return Ratios